Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02273960 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT02273960 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 46 participants.
The verdict
NCT02273960, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
Interventions
- DRUG BMS-986004 75 mg IV
- DRUG BMS-986004 225 mg IV
- DRUG BMS-986004 675 mg IV
- DRUG BMS-986004 1500 mg IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2014-11-17 |
| Est. Completion | 2018-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02273960
The ClinicalTrials.gov registry entry for NCT02273960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BMS-986004 75 mg IV is the first listed.
NCT02273960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02273960 about?
NCT02273960 is a clinical study titled "Study to Evaluate Safety and Efficacy in Adult Subjects With ITP". The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
What is the current status of trial NCT02273960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2014-11-17. Estimated completion is 2018-01-22.
What interventions are being tested in trial NCT02273960?
The interventions under investigation include: BMS-986004 75 mg IV (DRUG), BMS-986004 225 mg IV (DRUG), BMS-986004 675 mg IV (DRUG), BMS-986004 1500 mg IV (DRUG).
Who is sponsoring clinical trial NCT02273960?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.